Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • Germany(1,337/week)
    • Poland(926/week)
    • France(811/week)
    • Spain(653/week)
    • Italy(388/week)
    • View all (6,972/week)
  • News
    • United States(357/week)
    • Manufacturing(259/week)
    • Technology(288/week)
    • Energy(177/week)
    • Other Manufacturing(222/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

Lenalidomide

Jun 12, 2020
EHA25Virtual: Promising Treatment Results with Imetelstat, a Novel Telomerase Inhibitor, in Patients with Lower Risk Myelodysplastic Syndromes
Jun 01, 2020
New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021
May 22, 2020
Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included
Mar 17, 2020
National Research Cancer Institute UK Confirms Benefit Molecular Profiling in Multiple Myeloma
Mar 02, 2020
FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
Mar 02, 2020
FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
Mar 02, 2020
FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
Mar 02, 2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Mar 02, 2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Mar 02, 2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Feb 10, 2020
Janssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
Feb 03, 2020
GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
Jan 13, 2020
John Theurer Cancer Center Investigators Report Effectiveness of New Treatment for Refractory Multiple Myeloma
Jan 06, 2020
Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
Dec 16, 2019
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
Dec 10, 2019
DARZALEX® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Dec 09, 2019
DARZALEX® (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant
Dec 04, 2019
First Industry Datasets Submitted to ASH Research Collaborative Data Hub
Dec 04, 2019
International Myeloma Foundation Presents Research, Video Reports, Social Media Coverage at 2019 American Society of Hematology Meeting (ASH)
Nov 21, 2019
Catalent to Supply BeiGene's BTK Inhibitor BRUKINSA(TM) (zanubrutinib)
  •  
  • Page 1
  • ››

Latest News

Jun 3, 2023

Global Investment Casting Market Report 2023: Sector is Expected to Reach $20.1 Billion by 2028 at a CAGR of...

Jun 3, 2023

Black Bear Transmission Sells Mississippi Gas Gathering Assets

Jun 3, 2023

Veolia Academy Launches Free Online Training Program To Earn State Licenses For Well-Paying Water Jobs

Jun 2, 2023

Texas State University Signs Contract for 13 Emergency Communication Devices

Jun 2, 2023

Wallbox Announces Private Placement of Class A Ordinary Shares

Jun 2, 2023

Sidus Space Awarded Additional Space Hardware Manufacturing in Support of NASA’s Artemis Program and Space...

Jun 2, 2023

Columbus McKinnon to Webcast Fireside Chat at the Wells Fargo Industrials Conference

Jun 2, 2023

SAIC Board of Directors Declares Cash Dividend

View all News

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
  • PRIVACY POLICY
  • INFORMATION SECURITY POLICY
© 2023 EPICOS
Made by Wedia